Nome Químico: 2-((1-Hydroxy-2-(hydroxymethyl)-4-(4-octylphenyl)butan-2-yl)amino)-4-(4-octylphenyl)butanoic acid
Sorrisos: O=C(O)C(NC(CCC1=CC=C(CCCCCCCC)C=C1)(CO)CO)CCC2=CC=C(CCCCCCCC)C=C2
Inchi: InChI=1S/C56H52N8O8/c1-61(41-21-17-39(18-22-41)57-51(35-11-7-5-8-12-35)49-43-25-15-37(55(69)71-3)31-45(43)59-53(49)67)47(65)33-63-27-29-64(30-28-63)34-48(66)62(2)42-23-19-40(20-24-42)58-52(36-13-9-6-10-14-36)50-44-26-16-38(56(70)72-4)32-46(44)60-54(50)68/h5-26,31-32,57-58H,27-30,33-34H2,1-4H3,(H,59,67)(H,60,68)/b51-49-,52-50+
Fingolimod promotes angiogenesis and attenuates ischemic brain damage via modulating microglial polarization
KeShanga1JiaHeb1JingZoubChuanQinaLiLincLuo-QiZhouaLin-LinYangbLong-JunWudWeiWangaKe-BinZhanbDai-ShiTiana
Brain Research Volume 1726, 1 January 2020, 146509
Rapid Determination of Fingolimod Hydrochloride‑Related Substances and Degradation Products in API and Pharmaceutical Dosage Forms by Use of a Stability‑Indicating UPLC Method
N. Rajan · K. Anver Basha
Chromatographia (2014) 77:1545–1552
Development and validation of Immunomodulating drug Fingolimod by RPHPLC method with detailed force degradation study
Ravi V Ghediya1,2, Madhavi Patel1,2,3, Darshana Pandya1,2, Anamik K Shah1,2, Ranjan C Khunt
Chemistry & Biology Interface, 2016, 6, 4, 210-223